Inmunología y vacunas frente al SARS-CoV-2. Un hito científico histórico
DOI:
https://doi.org/10.66737/ier.zub.301Keywords:
SARS-Cov2, coronavirus, pandemic, vaccinesAbstract
Since the announcement on December 31, 2019 by the World Health Organization (WHO) of the appearance of a cluster of pneumonia cases of unknown origin in the city of Wuhan (China), the new SARS-CoV-2 coronavirus has spread worldwide and has caused the deadliest pandemic of
the 21st century, reaching more than 155 million infected and more than 3 million deaths worldwide by early May 2021 (Center for Systems Science and Engineering, Johns Hopkins University). This article will summarize the most relevant immunological aspects of this pandemic and how this knowledge, together with many others accumulated over decades, has been decisive in the development of several extremely safe and effective vaccines with an unprecedented speed in history (Table 1).
Downloads
References
Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU): Coronavirus COVID-19 Global Cases. Disponible en: https://coronavirus.jhu.edu/map.html Coronavirus (COVID-19) vaccinations. Disponible en: https://ourworldindata.org/covid-vaccinations
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., ... & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, 181(7), 489-1501.
Juul, S., Nielsen, E. E., Feinberg, J., Siddiqui, F., Jørgensen, C. K., Barot, E., ... & Jakobsen, J. C. (2021). Interventions for treatment of COVID-19: of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PloS one, 16(3), e0248132.
Moderna. (2020). Moderna announces first participant dosed in NIH-led phase 1 study of mRNA vaccine (mRNA-1273) against novel coronavirus. Moderna. Disponible en: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-firstparticipant-dosed-nih-led-phase-1-study (2020).
Monk, P. D., Marsden, R. J., Tear, V. J., Brookes, J., Batten, T. N., Mankowski, M., ... & Wilkinson, T. M. A. (2021). Inhaled Interferon Beta COVID-19 Study Group Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med, 9(2), 196-206.
Owen et al., (). Kuby Inmunología.
Rezaei, S., Fatemi, B., Karimi Majd, Z., Minaei, H., Peikanpour, M., Anjidani, N., ... & Mosaed, R. (2021). Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. Expert review of clinical immunology, 17(5), 499-511.
Tan, W., Zhao, X., Ma, X., Wang, W., Niu, P., Xu, W., ... & Wu, G. (2020). A novel coronavirus genome identified in a cluster of pneumonia cases— Wuhan, China 2019− 2020. China CDC weekly, 2(4), 61-62.
Tarke, A., Sidney, J., Methot, N., Zhang, Y., Dan, J. M., Goodwin, B., ...& Sette, A. (2021). Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. BioRxiv.
Tleyjeh, I. M., Kashour, Z., Damlaj, M., Riaz, M., Tlayjeh, H., Altannir, M., ...& Kashour, T. (2021). Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clinical Microbiology and Infection, 27(2), 215-227.
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., ... & Bijker, E. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.
WHO Emergency Committee (2020). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Jan 30, 2020.
Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., ... & Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature, 579(7798), 270-273.
Zuo, J., Dowell, A. C., Pearce, H., Verma, K., Long, H. M., Begum, J., ... & Moss, P. (2021). Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nature immunology, 22(5), 620-626.et al.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Iván Bernardo González (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en Zubía conservan los derechos de autor de sus trabajos y autorizan a la revista la primera publicación de los mismos.
Los artículos se publican bajo la licencia Creative Commons Atribución–No Comercial–Compartir Igual (CC BY-NC-SA), que permite su uso, distribución y reproducción en cualquier medio, siempre que se cite adecuadamente la autoría original, no se realice un uso comercial y se mantenga la misma licencia.
